News Release

A newly discovered hormone makes ovaries grow

The FASEB Journal suggests that human female eggs produce a previously unknown hormone, called R-spondin2, which promotes follicle development and stimulates ovary growth

Peer-Reviewed Publication

Federation of American Societies for Experimental Biology

Bethesda, MD—A newly discovered hormone produced by the eggs of human females may improve the effectiveness of current fertility treatments for women and possibly lead to entirely new treatments altogether. According to new research published in the June 2013 issue of The FASEB Journal, researchers from Stanford and Akira University in Japan identified a new hormone called "R-spondin2" that promotes follicle development and stimulates ovary growth.

"The finding of a new ovarian hormone produced by the oocytes capable of stimulating ovarian follicle growth could lead to new infertility treatments," said Aaron J. W. Hsueh, Ph.D., a researcher involved in the work from the Division of Reproductive and Stem Cell Biology in the Department of Obstetrics and Genecology at Stanford University Medical School in Stanford, California.

To make this discovery, Hsueh and colleagues analyzed all the proteins likely made by the eggs, and discovered a previously unknown hormone, called R-spondin2. The researchers then replicated this new hormone in test tubes and injected it into mice. The hormone stimulated growth of mouse ovarian cells, leading to the generation of mature eggs. These eggs were fertilized and led to successful pregnancies and the delivery of healthy pups. Then, human ovarian tissue was grafted into mice, and this also grew after treatment with this newly identified ovarian hormone, suggesting that the hormone could work in humans. The researchers speculate that when used in conjunction with the traditional Follicle Stimulating Hormone (FSH), this newly discovered ovarian hormone could lead to new infertility treatment options for those not responding well to FSH treatment alone.

"Infertility can be very frustrating for couples who have been trying to conceive for a very long time. The discovery of this new hormone is a potential game-changer in human fertility treatment," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal, "but further research is needed to determine its efficacy and safety in humans."

###

Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the most cited biology journals worldwide according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.

FASEB is composed of 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to its member societies and through collaborative advocacy.

Details: Yuan Cheng, Kazuhiro Kawamura, Seido Takae, Masashi Deguchi, Qing Yang, Calvin Kuo, and Aaron J. W. Hsueh. Oocyte-derived R-spondin2 promotes ovarian follicle development. FASEB J June 2013 27:2175-2184 ; doi:10.1096/fj.12-223412 ; http://www.fasebj.org/content/27/6/2175.abstract


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.